Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

7

Investigational

1

Other

1

Possibly Marketed Outside US

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

GABA receptor rho-1 subunit

1

GABA-B receptor 1

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

7

Phase II

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

7

Unknown

2

1982

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

penetration of radioactive iodine into the thyroid gland

7

Mild cognitive impairment

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Preventing

7

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Ciba-Geigy

1

Linnemann, Ed.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

10

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

10

FDA UNII

10

EPA CompTox

9

PUBCHEM

9

ECHA (EC/EINECS)

7

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

RESPIRATORY SYSTEM

1

SENSORY ORGANS

1

VARIOUS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ALL OTHER THERAPEUTIC PRODUCTS

1

COUGH AND COLD PREPARATIONS

1

OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ALL OTHER THERAPEUTIC PRODUCTS

1

EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS

1

OTHER OPHTHALMOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antidotes

1

Expectorants

1

Other ophthalmologicals

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

6

Principal Form

4

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 10 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

IODIDE ION

09G4I6V86Q

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

SGS-742

GBZ5UC0RME

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

GABA receptor rho-1 subunit

GABA-B receptor 1

Conditions:

Mild cognitive impairment

CGP-36742 (3-Aminopropyl-n-butyl-phosphinic acid) is one of the first GABAB receptor antagonists that can penetrate the blood-brain barrier after peripheral administration. Although its affinity for GABA B binding sites labeled with a tritiated agoni...

st is modest, being in the low micromolar range, it displays significant pharmacological activity when administered either orally or parenterally. CGP 36742 was effective in the learned helplessness paradigm in rats, dose-dependently improving the escape failures induced by the inescapable shocks, suggesting that it may have an antidepressant profile. CGP36742 displays pronounced cognition enhancing effects in Rhesus monkeys in active and passive avoidance paradigms, in an eight-arm radial maze and a Morris water maze and in a social learning task. CGP36742 blocks the late inhibitory postsynaptic potential and the paired-pulse inhibition of population spikes recorded from CA1 pyramidal neurons of the hippocampus of rats in vitro and in vivo. CGP36742 significantly enhances the release of glutamate, aspartate, glycine and somatostatin in vivo. Chronic administration of CGP36742 causes an up-regulation of GABA(B) receptors in the frontal cortex of rats. The effects of CGP36742 on cognition were investigated in a double-blind, placebo-controlled study undertaken as the first assessment of the efficacy of CGP36742 in 110 patients age 59–85 years with Mild cognitive impairment. The results showed significant improvement in working memory, psychomotor speed and attention with SGS742 as compared with placebo. SGS742 appeared to be safe and well tolerated in this study.

DICHLOROPHENYLPHOSPHINE

WRU258L1EW

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

PROPYLENE OXIDE

Y4Y7NYD4BK

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1982

Class (Stereo):

CHEMICAL (RACEMIC)

Propylene Oxide is a synthetic, highly-flammable, volatile, colorless liquid that is soluble in water and miscible with many organic solvents. The major use of propylene oxide is in the production of polyethers (the primary component of polyurethane ...

foams) and propylene glycol. Propylene oxide is also used in the fumigation of foodstuffs and plastic medical instruments and in the manufacture of dipropylene glycol and glycol ethers, as herbicides, as solvents, and in the preparation of lubricants, surfactants, and oil demulsifiers. Propylene Oxide is a chiral epoxide, although it is commonly used as a racemic mixture. Acute (short-term) exposure of humans and animals to propylene oxide has caused eye and respiratory tract irritation. Dermal contact, even with dilute solutions, has caused skin irritation and necrosis in humans. Propylene oxide is also a mild central nervous system (CNS) depressant in humans. Inflammatory lesions of the nasal cavity, trachea, and lungs and neurological effects have been observed in animals chronically (long-term) exposed to propylene oxide by inhalation.

Iodine, atomic

5D3DB66WM3

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

POTASSIUM PHOSPHIDE

2F09226A2C

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

ETHYLENEDIAMINE DIHYDRIODIDE

721M52NQ5L

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

Potassium iodide

1C4QK22F9J

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

Sodium iodide

F5WR8N145C

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

HYDROGEN IODIDE

694C0EFT9Q

Export Data
Search for Structure

Status:

US Approved Rx (1982)

First marketed in 1921

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

penetration of radioactive iodine into the thyroid gland

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1